Some of you may have seen the original News Release on January 19; however, for those who did not I'm presenting it here. Dana Farber announced that FDA Approval had been obtained for use of Zanubrutinib for those patients with relapsed CLL. The study showed that it was superior to the currently used Imbrutinib for those patients with relapsed CLL.
Here is the article:
dana-farber.org/newsroom/ne...
Carl